Agranulocytosis secondary to pentazocine therapy.
Agranulocytosis developed in three patients after prolonged oral pentazocine hydrochloride therapy. Two of the patients had a recurrence of their agranulocytosis within three weeks of reinstitution of pentazocine. Culture techniques in one patient indicate a probable metabolic effect.
D000380:Agranulocytosis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D010423:Pentazocine / Q000009:adverse effects*
D010423:Pentazocine